Wantstats
Company ProfilePremium

Becton, Dickinson and Company

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Becton, Dickinson and Company - Healthcare showcase

Year Founded & Workforce

1897

65,000 Employees

Industry

Healthcare

Services

Peripheral VascularPeripheral StentSwabsAutoinjectorCHG Cloth
B

Becton, Dickinson and Company Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Becton, Dickinson and Company Overview

Company Headquarters: New Jersey, US

Founded: 1897

Workforce: ~65,000

Company Working: Becton, Dickinson and Company (BD) is engaged in developing and manufacturing medical supplies, laboratory equipment, and diagnostic products. It operates in two segments, BD Medical and BD Life Sciences. Its life sciences segment offers products, such as liquid-based cytology systems, specimens, and blood collection products and systems, automated blood and tuberculosis culturing, molecular testing, rapid diagnostic assays, microbiology laboratory automation products, and fluorescence-activated cell sorters. Its medical segment comprises products, such as needle-free IV connectors and extension sets, peripheral IV and advanced peripheral catheters, acute dialysis catheters, vascular care and preparation products, and IV fluids.

BD has a strong presence throughout Eastern Europe, the Middle East, and Africa regions with technical specialists, sales specialists, technical service, and application support for its products. The company distributes its products in North America (Canada, Mexico, and the US), Europe (Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherland, Poland, Switzerland, Russia, United Kingdom, Turkey, Hungary, Italy), South America (Argentina, Brazil, Chile, and Colombia), Asia-Pacific (Australia, New Zealand, Indonesia, Korea, Malaysia, Philippines, Thailand, and Vietnam) and the Middle East and Africa (the Middle East, North Africa, and Africa).

Strategy

Becton, Dickinson and Company focuses to achieve growth by expanding its product portfolio and geographic reach through both organic growth and acquisitions. The company is investing heavily in research and development to develop new products and technologies that can improve patient outcomes and reduce healthcare costs. In addition, Becton, Dickinson and Company is focused on expanding its market share in emerging markets with increasing healthcare needs, such as Asia and Latin America. The company is also pursuing strategic partnerships and collaborations to leverage complementary capabilities and expand its market reach, with a focus on expanding its presence in the oncology and immunology spaces.

Company Snapshot

$16,074M

Revenue

65,000

Employees

1897

Founded

New Jersey, US

Headquarters

SWOT Analysis

Strengths

  • Competitive products with a solid sales growth outlook
  • Strong cost controls
  • Well established distribution channel
  • Focused research and development capabilities
  • Market leadership
  • Improved performance of the laboratory products and services segment
  • Strong research and development capabilities High market share Improved performance of its laboratory products and services segment
  • Strong research and development capabilities
  • Improved performance of its laboratory products and services segment
  • Improved performance of laboratory products and the services segment
  • Strong research and development capabilities High market share
  • Strong R&D capabilities
  • Diversified manufacturing operations globally
  • Highly successful at ‘go to market strategies’ for its products
  • Accelerated strategic efforts to simplify network, portfolio, and processes
  • Strong brand recognition and a diversified product portfolio in the medical technology and healthcare sectors.

Weaknesses

  • Large amount of international sales causes fluctuating currency exchange rates to have a material impact on growth
  • Involvement in patent infringement litigation ruining the brand image
  • Increasing debt burden
  • Patent infringement and other disputes
  • Increasing debt burden Patent infringement and other legal disputes
  • Patent infringement and other legal disputes
  • Increasing liabilities
  • Increasing debt burden and gaps in the product range sold by the company
  • High dependence on a limited number of large customers, which may increase risk and limit growth opportunities.

Opportunities

  • International growth for the medical supplies industry
  • Emerging markets operations
  • New product launches
  • Inorganic growth initiatives
  • New products and services
  • Agreements and collaborations
  • Partnerships and collaborations for product line expansion
  • Global in-vitro diagnostic market
  • Rising partnerships and collaborations for product line expansion
  • Introduction of new technology by the company provides an opportunity to practice differentiated pricing strategy in the market
  • Stable free cash flow of the company is providing opportunities to invest in adjacent product segments
  • Growing demand for medical technologies, especially in emerging markets with increasing healthcare needs.
  • Expansion into new product categories and therapeutic areas, such as oncology and immunology.

Threats

  • Alliance of intensify competition
  • Fluctuating economies
  • Government regulations on medical devices
  • Competitive environment
  • Rapid technological changes
  • Regulatory environment
  • High competition Rapid technological changes Changing regulatory environment
  • High competition
  • Changing regulatory environment
  • Downturn in global economic conditions adversely affects the company’s operations
  • Competitive environment
  • Rising raw material prices
  • Fluctuating economy due to COVID-19
  • Changing regulatory scenario
  • Intense competition from other medical technology companies in the global market.
  • Changes in regulatory policies or reimbursement environment, which may affect the demand and pricing for the company's products and services.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
March 2015AcquisitionCompleted the acquisition of CareFusion Corporation (CareFusion) for $12.2 billion. CareFusion will operate as a wholly-owned subsidiary of BD. The acquisition is intended to enhance the medication management and patient safety solutions provided by BD.
March 2015AcquisitionAnnounced the acquisition of CRISI Medical Systems, a medical technology company focused on providing safety and delivery of IV injectable medications. The acquisition will strengthen BD’s position in addressing preventable medication errors and improve care delivery efficiencies.
October 2014AcquisitionAnnounced the acquisition of GenCellBio systems, an Irish biotech company that has developed proprietary technologies that address key biological analysis protocols, for an undisclosed consideration. The acquisition is expected to improve the BD’s Next Generation Sequencing line of products.
December 2017AcquisitionBD acquired C. R. Bard, Inc. for USD 24 billion. With this acquisition, the company aimed to become a leader in the healthcare industry. This acquisition made BD generate annual revenue of approximately USD 16 billion in 2017.
July 2017Product LaunchBD launched new technology (BD Kiestra urine culture app) to automatically report and release negative urine cultures. The BD Kiestra urine culture app will integrate with BD BBL plated media to determine the growth of the urine sample. The BD Kiestra urine culture app can also be used for work cell automation and total lab automation solution. This product launch will aid the company in enhancing its microbiology portfolio.
–InvestmentBecton, Dickinson, and Company announced an investment of USD 24 million from the US department of defense in collaboration with the US department of Health and Human Services to provide support for the scale up of US manufacturing facilities for BD Veritor solution for rapid detection of SARS-CoV-2
November-2022ExpansionGovernment representatives from Mexico and Baja California joined BD (Becton, Dickinson and Company), a major global provider of medical technology, to officially open a new $38.6 million manufacturing facility in Tijuana that will create tools and innovations that enhance medication safety in healthcare settings.
May-2022PartnershipA strategic alliance between BD (Becton, Dickinson and Company), a major worldwide medical technology firm, and Babson Diagnostics, a science-first health care technology company, has expanded. This will allow patients to obtain blood samples at home for diagnostic testing.

Product Offering

  • Becton, Dickinson and Company
    • Peripheral Vascular
    • Peripheral Stent
    • Swabs
    • Autoinjector
    • CHG Cloth
    • Immunoassay products
    • Bead-based Immunoassay
    • BD ELISA Reagents
    • BD ELISPOT Reagents
    • Cell Culture Tools
    • Culture Media
    • Reagents
    • Safety Lancet
    • Closed Vial Access Devices
    • Closed Syringe Safety Devices
    • Closed Bag/Line Access Devices
    • BD Medical
    • Lab automation
    • Global Immunoassays In R&D Market
    • Breast Biopsy Products

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Revenue rose from USD 16,074 Mn in 2020 to USD 18,870 Mn in 2022.
Becton, Dickinson and Company — By Business Segment
Series (USD Mn)202020212022
Revenue16,07419,13118,870
R&D Expenditure1,0391,2791,256

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →